ArticleHealth science reports2019

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).

Tarik Asselah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.